Antoni van Leeuwenhoek hospital brings comprehensive DNA test closer for all cancer patients
This year, Antoni van Leeuwenhoek hospital joined forces with Hartwig Medical Foundation to deploy the most comprehensive DNA test available in the world for regular diagnostic procedures. This test identifies which patients are suited for standard cancer treatments, and which patients could benefit from experimental treatments. On February 10, the Dutch House of Representatives will discuss how this test can be made available to all cancer patients in the Netherlands as soon as possible.
“A single test is enough to conduct a comprehensive analysis of the entire DNA of the tumor,” explains Emile Voest, an internist-oncologist at Antoni van Leeuwenhoek. “We examine the mutations in DNA to find clues to the best possible treatments, including both existing treatments and the treatments of the future.” The test can currently only be requested for Antoni van Leeuwenhoek patients with metastatic or suspected metastatic cancer who also have an indication for a broad molecular diagnostic procedure.
From research to practical application
The comprehensive DNA test was developed together with Hartwig Medical Foundation, whose goal is to ensure that every cancer patient receives the right and most effective treatment. The test has been performed on thousands of patients in recent years and provides more and better information than other tests used to date. “We are proud that, together with Hartwig Medical Foundation, we have made the comprehensive DNA test ready for use in standard diagnostics,” says Gerrit Meijer, Principal Investigator at Antoni van Leeuwenhoek. “Moreover, the test produces important information for a continuously learning healthcare system, in which we will be able to treat future patients even more effectively.”
One test for today and the future
“We want to extract the maximum amount of information from the patient’s tumor,” explains Antoni van Leeuwenhoek pathologist Kim Monkhorst.“This test is the best available tool for that. We only need one tissue sample with sufficient tumor cells. Because we literally analyze the entire genome, including parts of the DNA that show mutations of which we don’t yet know the importance, this test is always up to date and future-proof. This means that new discoveries can also lead to potential new treatments for patients who were tested in the past.”
Emile Voest: “Our research has proven that it is workable in practice and that it is of great importance to our patients. We are gaining valuable information about patients and expect to be able to target treatments more effectively in the near future. We are also building a database from which we will learn even more about cancer.”
Policy document consultation
From 9.30 a.m. to 12 noon on February 10, Parliament has discussed the draft policy document presented by Ministry of Health, Welfare and Sport committee members Sazias, Van den Berg and Veldman on the urgency of introducing a comprehensive personal DNA profile.
Points for decision:
- Plan of action to accelerate the incorporation of best practices in proven effective care in the standard healthcare system.
- Task force charged with examining what is needed to make comprehensive DNA testing available, as soon as possible, to every cancer patient prior to a treatment decision.
Erasmus MC Cancer Institute introduces comprehensive DNA testing for CUP cancer patients in EMBRAZE region
The Erasmus MC Cancer Institute has started using comprehensive DNA testing for carcinoma of unknown primary (CUP) cancer patients in …
GenomeWeb: ‘Dutch Team Looks to Drug Repurposing to Improve Patient Outcomes, Lower Costs’
The project is an attempt to address the rising healthcare costs associated with new cancer drugs and to identify biomarkers …
Whole genome sequencing to improve individual cancer treatment in Finland
Since August 2019, Docrates, a private cancer center in Finland, uses the whole genome sequencing test from Hartwig Medical Foundation to …
The complete DNA test is an important step toward treating forms of cancer that currently cannot be treated with targeted drugs.